top of page

Mereo BioPharma reports positive outcome of phase 1 drug interaction study with acumapimod

UK-based Mereo BioPharma Group has reported positive results of its Phase 1 drug interaction study with acumapimod, the active compound in its p38 MAP kinase inhibitor BCT-197.

BCT-197 is currently in a Phase 2 study for the treatment of acute exacerbations of COPD (AECOPD).



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page